2- (2- (2- dimethylaminothiazol- 5- yl)ethenyl)- 6- (2- (fluoro)ethoxy)benzoxazole

08/01/2013 - "A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography."
01/01/2010 - "In addition, binding characteristics of BF-227 to amyloid deposits were examined using postmortem AD brain samples. "
01/01/2010 - "Amyloid plaque burden was evaluated using [(11)C]BF-227 PET in AD, MCI and aged normal controls. "
04/01/2007 - "These findings suggest that BF-227 is a promising PET probe for in vivo detection of dense amyloid deposits in AD patients."
04/01/2007 - "Voxel-by-voxel analysis of PET images revealed that cortical BF-227 retention in AD patients is distributed primarily to the posterior association area of the brain and corresponded well with the preferred site for neuritic plaque depositions containing dense Abeta fibrils. "

07/01/2013 - "BF-227 shows mainly binding to site 3 and FDDNP shows only some binding to site 2. Different amyloid tracers may provide new insight into the pathophysiological mechanisms in the progression of Alzheimer's disease."
07/01/2013 - "The binding properties of the amyloid tracers FDDNP, AV-45, AV-1 and BF-227 were also compared with those of (3)H-Pittsburgh compound B in the frontal cortices of patients with Alzheimer's disease. "
01/01/2013 - "For instance, styrylbenzoazole derivative BF-227, currently used as an amyloid imaging probe of positron emission tomography in Alzheimer disease, is useful also for the diagnosis of Gerstmann-Sträussler-Scheinker syndrome. "
05/01/2010 - "We recently developed a novel PET tracer, (11)C-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole ([(11)C]BF-227), and had success with in vivo detection of amyloid plaques in Alzheimer's disease (AD) brains (Kudo et al. in J Nucl Med 8:553-561, 2007). "
05/01/2010 - "Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET."

10/15/2009 - "The neuritic plaque burden and gray matter losses were evaluated using [11C]BF-227-PET and VBM-MRI in 12 healthy controls, 13 subjects with mild cognitive impairment (MCI), including 6 who converted to AD and 7 who did not convert, and 15 AD patients. "
05/01/2010 - "Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET."
01/01/2010 - "Voxel-based analysis of amyloid positron emission tomography probe [C]BF-227 uptake in mild cognitive impairment and alzheimer's disease."
01/01/2010 - "To determine early brain changes in the distribution of an amyloid positron emission tomography (PET) probe, (11)C-labeled BF-227 or [(11)C]BF-227, in order to accurately predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). "

01/01/2018 - "Amyloid-Beta Radiotracer [18F]BF-227 Does Not Bind to Cytoplasmic Glial Inclusions of Postmortem Multiple System Atrophy Brain Tissue."

01/01/2013 - "Brain accumulation of amyloid β protein visualized by positron emission tomography and BF-227 in Alzheimer's disease patients with or without diabetes mellitus."